Grifols SA Ordinary Shares - Class A GIFLF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GIFLF is a good fit for your portfolio.
News
-
Johnson Fistel, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
-
Grifols shares rebound after KPMG greenlights accounts in wake of short-seller's report
-
Grifols' shares plunge further on short-seller's new report
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF
-
Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt
-
Grifols Shares Rise on Potential Sale of Shanghai RAAS Stock for $1.5 Billion
Trading Information
- Previous Close Price
- $9.35
- Day Range
- $8.46–9.12
- 52-Week Range
- $7.46–15.80
- Bid/Ask
- $8.50 / $9.50
- Market Cap
- $5.75 Bil
- Volume/Avg
- 4,633 / 4,707
Key Statistics
- Price/Earnings (Normalized)
- 32.91
- Price/Sales
- 0.81
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Core
- Total Number of Employees
- 23,737
- Website
- https://www.grifols.com
Competitors
Valuation
|
Metric
|
GIFLF
|
CSL
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 32.91 | 28.43 | 14.27 |
Price/Book Value | 0.89 | 5.28 | 1.67 |
Price/Sales | 0.81 | 6.32 | 2.53 |
Price/Cash Flow | 9.20 | 32.99 | 13.63 |
Price/Earnings
GIFLF
CSL
PFE
Financial Strength
|
Metric
|
GIFLF
|
CSL
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.72 | 0.95 | 0.58 |
Current Ratio | 2.48 | 2.15 | 0.91 |
Interest Coverage | 1.28 | 7.21 | 0.74 |
Quick Ratio
GIFLF
CSL
PFE
Profitability
|
Metric
|
GIFLF
|
CSL
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 1.30% | 8.11% | 4.98% |
Return on Equity (Normalized) | 4.69% | 18.17% | 10.90% |
Return on Invested Capital (Normalized) | 3.45% | 10.94% | 7.28% |
Return on Assets
GIFLF
CSL
PFE
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Bnpzcwkmk | Nphcf | $695.3 Bil | |
JNJ
| Johnson & Johnson | Wxwrnrqmm | Tjgr | $359.3 Bil | |
MRK
| Merck & Co Inc | Rtbcbkts | Tpgfk | $321.5 Bil | |
ABBV
| AbbVie Inc | Kdlzvgv | Cvb | $297.3 Bil | |
AZN
| AstraZeneca PLC ADR | Dxbnnlsxh | Stt | $215.8 Bil | |
RHHBY
| Roche Holding AG ADR | Wcfglrwmb | Mgvc | $203.2 Bil | |
NVS
| Novartis AG ADR | Khnzzvddm | Nxyd | $196.0 Bil | |
PFE
| Pfizer Inc | Yrkvbhzd | Vgtf | $148.7 Bil | |
AMGN
| Amgen Inc | Mvygdkcrj | Rrc | $145.8 Bil | |
SNY
| Sanofi SA ADR | Mcgkhmq | Lld | $117.3 Bil |